|
|
73 High St.
Buffalo, NY 14203 USA
phone:716-849-6810
fax:716-849-6820
|
|
| Symbol |
CBLI |
| Exchange |
Nasdaq |
| Founded |
2003 |
| Employees |
52 |
|
|
| www.cbiolabs.com
|
|
| Research Sector |
Biotech Specialty Pharma |
|
 |
| Summary Description |
| Drugs: Medical and defense applications |
|
| Management |
| Michael Fonstein, Ph.D., Chief Executive Officer and President; Andrei Gudkov, Ph.D., D. Sci., Chief Scientific Officer; Yakov Kogan, Ph.D., MBA, Chief Operating Officer; C. Neil Lyons, Chief Financial Officer; Michael Kurman, MD, Chief Medical Officer |
| |
|
|
|
|
|
|
|
| Keywords |
| drugs, medical, cancer institute, radiobiology, protectans, curaxins |
|
|
|
| Description |
|
Established in 2003, Cleveland BioLabs, Inc. (Nasdaq:CBLI) is a biotechnology company leveraging its proprietary discoveries around programmed cell death to develop a pipeline of drugs for multiple medical and defense applications.The company has strategic partnerships with the Cleveland Clinic, Roswell Park Cancer Institute, ChemBridge Corporation and the Armed Forces Radiobiology Research Institute.CBLI�s pipeline includes products from two primary families of compounds: Protectans and Curaxins. Protectans are being developed as drug candidates that protect normal tissues from acute stresses such as radiation, chemotherapy and ischemias (pathologies developed as a result of blocking blood flow to a part of the body). Curaxins are being developed as anticancer agents that could act as mono-therapy drugs or in combination with other existing anticancer therapies. |
|
| Products / Services |
Protectan CBLB502 for Acute Radiation Syndrome
Protectan CBLB502 for supportive care in cancer treatment
Protectan CBLB612 for induction and mobilization of hematopoeitic stem cells
Curaxin CBLC137 for cancer treatment
|
|
| Technology / Differentiation |
| The scientific foundation of Cleveland BioLabs?s product development efforts is based upon proprietary discoveries of the molecular mechanisms underlying a form of cell death called apoptosis. Apoptosis is a highly specific and tightly regulated form of cell death that can be initiated by a variety of external and internal stresses including exposure to radiation or toxic chemicals. For example, exposure to high doses of radiation is lethal due to massive cell loss through apoptosis in radiosensitive tissue such as the hematopoietic (HP) system and the gastrointestinal (GI) tract (?Acute Radiation Syndrome? (ARS)). In addition, apoptotic death of bystander non-tumor cells accounts for the dose-limiting toxicity of anti-cancer radio- and chemotherapy that affects more than 70 percent of patients. |
|
| Market / Customers |
CBLI serves two distinct markets or customer groups with its pipeline of drugs: Medical Oncology market providing both potential cancer treatments and supportive care agents; and Defense market, providing a single use radiation antdote for government stockpiling.
|
|
| Competitors / Substitutes / Alternatives |
In the medical market, competitors for supportive care agents include G-CSF in various forms or other hematological growth factors, or other antiradiation agents such as amifostine or ethyol. In the defense market, there are no approved drugs for acute radiation syndrome and no other close compeitiors in development.
|
|
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members
